Benicar (Olmesartan Medoxomil): A Comprehensive Overview > 공지사항

• 목록
• 답변
• 글쓰기
• 게시판 리스트 옵션
  • 수정
  • 삭제

Benicar, known generically as olmesartan medoxomil, is an angiotensin II receptor blocker (ARB) used primarily for the management of hypertension. It was approved by the U.S. Food and Drug Administration (FDA) in 2002 and has since become a widely prescribed antihypertensive agent. This report provides a concise yet thorough examination of Benicar, Furosemide (frusemide) 100mg covering its pharmacology, clinical indications, safety profile, and relevant controversies.

Pharmacology and Mechanism of Action
Olmesartan medoxomil is a prodrug that is rapidly converted to its active metabolite, olmesartan, during absorption from the gastrointestinal tract. Olmesartan selectively blocks the binding of angiotensin II to the AT1 receptor in vascular smooth muscle and adrenal cortex. This antagonism prevents the vasoconstrictor and aldosterone-secreting effects of angiotensin II, leading to a reduction in peripheral vascular resistance, decreased blood pressure, and lowered aldosterone levels, which in turn reduces sodium and water retention. Unlike ACE inhibitors, ARBs do not inhibit bradykinin breakdown, thus the incidence of cough is significantly lower. Benicar has a long half-life (approximately 13 hours), allowing once-daily dosing, and its antihypertensive effect persists for 24 hours.

Clinical Indications and Efficacy
The primary indication for Benicar is hypertension, either as monotherapy or in combination with other antihypertensive agents. Clinical trials have demonstrated its efficacy in reducing both systolic and diastolic blood pressure across diverse patient populations, including elderly patients, African Americans, and those with diabetes. The BENICAR study and other large trials have shown comparable efficacy to other ARBs and ACE inhibitors, with a favorable tolerability profile. Additionally, Benicar has been studied for its potential renal protective effects in patients with type 2 diabetes and nephropathy, although its use in this context is not an official FDA indication and requires careful monitoring. It is also available in fixed-dose combinations with hydrochlorothiazide (Benicar HCT) or amlodipine (Azor), which enhance blood pressure control in patients not adequately managed on monotherapy.

Dosing and Administration
Benicar is available in tablet strengths of 5 mg, 20 mg, and 40 mg. The usual starting dose is 20 mg once daily for patients without volume depletion. The dose may be increased to 40 mg after two weeks if needed. In patients with possible intravascular volume depletion (e.g., those on diuretics), a lower starting dose of 5 mg is recommended. Maximal antihypertensive effect is typically seen within two weeks of initiating therapy. Once-daily dosing improves compliance and provides consistent blood pressure control.

Safety and Adverse Effects
Benicar is generally well-tolerated. The most common adverse reactions include dizziness, headache, and upper respiratory infection, though these occur at rates similar to placebo. Because of its mechanism, orthostatic hypotension may occur, particularly in volume-depleted patients. Hyperkalemia is a potential concern, especially in patients with renal impairment or those taking potassium-sparing diuretics or potassium supplements. Renal function should be monitored periodically. As with all ARBs, Benicar should be avoided during pregnancy due to the risk of fetal harm (oligohydramnios, fetal renal dysfunction, and skull ossification defects), particularly in the second and third trimesters. It is classified as pregnancy Category D for the second and third trimesters.

A noteworthy safety issue emerged in the early 2010s regarding a potential association between olmesartan and sprue-like enteropathy. Reports described patients developing severe, chronic diarrhea with significant weight loss, often requiring hospitalization and parenteral nutrition. Biopsies showed villous atrophy suggestive of celiac disease but with negative serology. Symptoms typically resolved after discontinuation of olmesartan. In 2013, the FDA issued a Drug Safety Communication warning that olmesartan can cause intestinal problems (sprue-like enteropathy) that may develop months to years after starting the drug. This adverse effect appears to be rare but is important to recognize, as it can be misdiagnosed as refractory celiac disease. Because of this risk, Benicar is not recommended for first-line treatment in patients with pre-existing gastrointestinal disorders.

Drug Interactions
Benicar has few clinically significant drug interactions. It may increase serum lithium levels, so lithium levels should be monitored if co-administered. Nonsteroidal anti-inflammatory drugs (NSAIDs), including COX-2 inhibitors, may reduce the antihypertensive effect of ARBs and, in elderly or volume-depleted patients, may increase the risk of renal impairment. When used with potassium supplements or potassium-sparing diuretics, hyperkalemia risk increases.

Controversies and Litigation
The most notable controversy surrounding Benicar is the aforementioned sprue-like enteropathy. After the FDA warning, a number of product liability lawsuits were filed against the manufacturer, Daiichi Sankyo, alleging failure to adequately warn patients and physicians about this risk. Some studies have estimated the incidence of olmesartan-associated enteropathy to be around 1 per 1,000 patient-years, though estimates vary. Other studies have shown no significant increase in gastrointestinal events compared to other antihypertensives. Despite the litigation, Benicar remains available on the market, and its benefit in lowering blood pressure is considered to outweigh the rare risk of enteropathy for most patients. However, physicians are advised to consider this risk when prescribing, especially in patients with unexplained gastrointestinal symptoms.

Conclusion
Benicar (olmesartan) is an effective and generally safe antihypertensive agent belonging to the ARB class. Its once-daily dosing, low incidence of cough, and proven efficacy make it a valuable option for managing hypertension. However, the rare but serious risk of sprue-like enteropathy necessitates caution and monitoring. Prescribers should be aware of this potential adverse effect and consider alternative therapies in patients at high risk or those who develop persistent diarrhea. Overall, Benicar remains a relevant medication in the treatment of hypertension when used appropriately and with informed clinical judgment.